NASDAQ:PVLA
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. reported net income of −$41.7M in fiscal 2025. The diluted share count rose 405.5%.Summary generated from Palvella Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 31, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−92.1%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+405.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 31 | 26 | 43 | n/a | n/a |
| Operating income | −52 | −43 | −12 | −14 | −39 |
| Net income | −46 | −33 | 19 | −17 | −42 |
| Free cash flow | −9 | −61 | −14 | n/a | n/a |
Recent filings
- 4Insider transaction report
Sep 18, 2026 - 4Insider transaction report
Sep 15, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 4, 2026 - 8-KResults of operations and financial condition
Aug 4, 2026 - 8-KOther events
Jul 14, 2026 - 8-KDirector or officer change
Jun 30, 2026 - 8-KDirector or officer change
Jun 16, 2026 - 8-KOther events
May 20, 2026